Acta Scientific Cancer Biology

OpinionVolume 2 Issue 6

Pancreatic Cancer Treatment- Search for the Elusive Silver Bullet

Christopher S Gondi

Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

*Corresponding Author: Christopher S Gondi, Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.

Received: July 18, 2018; Published: July 28, 2018

Citation: Christopher S Gondi. “Pancreatic Cancer Treatment- Search for the Elusive Silver Bullet ". Acta Scientific Cancer Biology 2.6 (2018).

  Pancreatic Ductal Adeno Carcinoma (PDAC) is the fourth most common cause of cancer deaths in the United States and is gaining importance worldwide as the survival rates are very poor for all four stages combined. The combined 1-year survival is only about 25% and the 5-year survival is less than 8%. It has been often observed that PDAC tumors reoccur after surgery and chemotherapy. These new tumors tend to be chemo-resistant, leading to poor survival rates, which have not changed in the last 40 years. A major hallmark of pancreatic cancer is extensive local tumor invasion, early systemic dissemination, and extremely poor response to chemotherapy. The basis for these adverse characteristics is not well understood. Identifying the mechanisms involved in chemoresistance and tumor recurrence will enable the development of better strategies to combat this disease.

  One of the main reasons why pancreatic cancer is so deadly is that by the time it is diagnosed it usually is too late. Unlike other cancers such as lung and colon, which present numerous symptoms, pancreatic cancer at an early stage shows almost no symptoms. Symptoms can be as common as abdominal pain, weight loss, and loss of appetite; because the symptoms are so common it is very difficult to determine whether a person has pancreatic cancer or something else. Constant persistent symptoms accompanied by more severe indications such as jaundice is usually when a patient realizes that something is wrong.

Copyright: © 2018 Christopher S Gondi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Member In



News and Events


  • Submission Timeline for Regular Issue
    The last date for submission of articles for regular Issues is November 30, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US